Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02652754 · ClinicalTrials.gov registry record · Phase 1
Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Diabetic Foot Ulcers
A Phase 1 study of Diabetic Foot Ulcers, sponsored by Xequel Bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 3
- Study locations
NCT02652754: Completed Phase 1 study of Diabetic Foot Ulcers, sponsored by Xequel Bio.
NCT02652754 is a Phase 1 study of Diabetic Foot Ulcers that has completed, run by Xequel Bio. The registered enrollment target is 16 participants, below the 233-participant average among 12 other Diabetic Foot Ulcers trials with a reported enrollment target (93% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02652754, a Phase 1 study of Diabetic Foot Ulcers, has completed, sponsored by Xequel Bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine the systemic exposure of Granexin® gel after topical application to human subjects' diabetic foot ulcers.
Conditions Studied
Interventions
- DRUG Granexin® gel
Study Locations (3)
Georgia
- Aiyan Diabetes Center - Augusta
South Carolina
- Spartanburg Regional Healthcare System - Spartanburg
Virginia
- Salem VA Medical Center - Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2015-09 |
| Est. Completion | 2018-05 |
| Phase | Phase 1 |
What the finished NCT02652754 record still lists
NCT02652754 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 233-participant average among 12 other Diabetic Foot Ulcers trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Diabetic Foot Ulcers appearing as the primary indexed condition, and to 1 intervention - of which Granexin® gel is the first listed.
NCT02652754 reports a single indexed study location in Georgia, South Carolina, Virginia.
Frequently Asked Questions
What is clinical trial NCT02652754 about?
NCT02652754 is a clinical study titled "Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Diabetic Foot Ulcers". The purpose of this study is to determine the systemic exposure of Granexin® gel after topical application to human subjects' diabetic foot ulcers.
What is the current status of trial NCT02652754?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2015-09. Estimated completion is 2018-05.
What conditions does trial NCT02652754 study?
This clinical trial studies the following conditions: Diabetic Foot Ulcers.
What interventions are being tested in trial NCT02652754?
The interventions under investigation include: Granexin® gel (DRUG).
Who is sponsoring clinical trial NCT02652754?
This trial is sponsored by Xequel Bio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02652754 being conducted?
This trial has 3 study locations across Georgia, South Carolina, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Foot Ulcers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02652754's enrollment target sits among peer trials
16 13th of 12 the lowest of 12 other Diabetic Foot Ulcers trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Foot Ulcers trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Wound Healing Endpoint and Recurrence
ACTIVE NOT RECRUITING · Phase 1
-
Phase II Study to Evaluate Efficacy and Safety of AMP Peptide PL-5 in Mild Infections of Diabetic Foot Ulcers
ACTIVE NOT RECRUITING · Phase 2
-
Clinical Trials of Footwear in Patients With Diabetes-Study Arm 2,3
COMPLETED · Phase 2
-
A Prospective Study of Endothelial Dysfunction and Diabetic Foot Ulcer Risk
COMPLETED
-
MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers
COMPLETED · Phase 3
-
Hyperspectral Imaging to Assess and Predict Diabetic Foot Ulcers
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia